Complete Guide to Trodelvy Pharmacokinetics
Overview
Trodelvy is a Antibody-Drug Conjugate (ADC) used in the Oncology therapeutic area. It is indicated for Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. Population PK simulator for sacituzumab govitecan (SG, Trodelvy) — TROP2-directed ADC for TNBC, HR+/HER2- breast cancer, and urothelial cancer. Triple-analyte model: intact ADC, free SN-38 payload (with UGT1A1 genotype covariate), and total antibody with time-dependent clearance. Based on Sathe et al. Clin Pharmacokinet 2024.
Mechanism of Action
Trodelvy exerts its pharmacological effect by targeting TROP2. As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) model for Trodelvy characterizes the time-course of drug concentrations following IV Infusion administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Trodelvy is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload, understanding the pharmacokinetics of Trodelvy is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Trodelvy pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Trodelvy PK Simulator
Explore Trodelvy pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Trodelvy?
The elimination half-life of Trodelvy depends on patient-specific factors. Use our interactive Trodelvy PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Trodelvy administered?
Trodelvy is administered via the IV Infusion route. It is indicated for Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Trodelvy?
Key pharmacokinetic parameters for Trodelvy include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) model to characterize the pharmacokinetics of Trodelvy.
Can I simulate Trodelvy dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Trodelvy PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.